Annotation Detail

Information
Associated Genes
RET
Associated Variants
RET UNKNOWN
RET FUSION
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset. This study was a multi-center, open-label, phase II clinical trial to examine the safety and efficacy of Vandetanib (300 mg/d) in RET positive NSCLC patients (confirmed by FISH), Primary endpoint was the objective response rate. 18 patients were enrolled, the majority were a heavily pretreated population. Among the 17 evaluable patients, three had a partial response (ORR = 18%) and eight had a stable disease (DCR = 65%). Among these patients, the PR or SD was durable for more than 6 months in 8 patients. Vandetanib also showed a PFS of 4.5 months, and an OS of 11.6 months during a median follow-up duration of 14 months.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/4848
Gene URL
https://civic.genome.wustl.edu/links/genes/42
Variant URL
https://civic.genome.wustl.edu/links/variants/1687
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Vandetanib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27803005
Drugs
Drug NameSensitivitySupported
VandetanibSensitivitytrue